Wikipedia preview
出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2015/12/14 13:43:15」(JST)
wiki en
| This article may be too technical for most readers to understand. Please help improve this article to make it understandable to non-experts, without removing the technical details. The talk page may contain suggestions. (January 2013) |
| Dihydrofolate reductase | |||||||||
|---|---|---|---|---|---|---|---|---|---|
|
Crystal structure of chicken liver dihydrofolate reductase. PDB entry 8dfr
|
|||||||||
| Identifiers | |||||||||
| EC number | 1.5.1.3 | ||||||||
| CAS number | 9002-03-3 | ||||||||
| Databases | |||||||||
| IntEnz | IntEnz view | ||||||||
| BRENDA | BRENDA entry | ||||||||
| ExPASy | NiceZyme view | ||||||||
| KEGG | KEGG entry | ||||||||
| MetaCyc | metabolic pathway | ||||||||
| PRIAM | profile | ||||||||
| PDB structures | RCSB PDB PDBe PDBsum | ||||||||
| Gene Ontology | AmiGO / EGO | ||||||||
|
|||||||||
| Dihydrofolate reductase | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Identifiers | |||||||||
| Symbol | DHFR_1 | ||||||||
| Pfam | PF00186 | ||||||||
| Pfam clan | CL0387 | ||||||||
| InterPro | IPR001796 | ||||||||
| PROSITE | PDOC00072 | ||||||||
| SCOP | 1dhi | ||||||||
| SUPERFAMILY | 1dhi | ||||||||
|
|||||||||
| R67 dihydrofolate reductase | |||||||||
|---|---|---|---|---|---|---|---|---|---|
|
High-resolution structure of a plasmid-encoded dihydrofolate reductase from E.coli. PDB entry 2gqv
|
|||||||||
| Identifiers | |||||||||
| Symbol | DHFR_2 | ||||||||
| Pfam | PF06442 | ||||||||
| InterPro | IPR009159 | ||||||||
| SCOP | 1vif | ||||||||
| SUPERFAMILY | 1vif | ||||||||
|
|||||||||
| Dihydrofolate reductase | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Ribbon diagram of human dihydrofolate reductase in complex with folate (blue). From PDB: 1DRF.
|
|||||||||||||
|
|||||||||||||
| Identifiers | |||||||||||||
| Symbols | DHFR ; DHFRP1; DYR | ||||||||||||
| External IDs | OMIM: 126060 MGI: 94890 HomoloGene: 56470 ChEMBL: 202 GeneCards: DHFR Gene | ||||||||||||
| EC number | 1.5.1.3 | ||||||||||||
|
|||||||||||||
| Orthologs | |||||||||||||
| Species | Human | Mouse | |||||||||||
| Entrez | 1719 | 13361 | |||||||||||
| Ensembl | ENSG00000228716 | ENSMUSG00000021707 | |||||||||||
| UniProt | P00374 | P00375 | |||||||||||
| RefSeq (mRNA) | NM_000791 | NM_010049 | |||||||||||
| RefSeq (protein) | NP_000782 | NP_034179 | |||||||||||
| Location (UCSC) | Chr 5: 80.63 – 80.65 Mb |
Chr 13: 92.35 – 92.39 Mb |
|||||||||||
| PubMed search | [1] | [2] | |||||||||||
|
|||||||||||||
Dihydrofolate reductase, or DHFR, is an enzyme that reduces dihydrofolic acid to tetrahydrofolic acid, using NADPH as electron donor, which can be converted to the kinds of tetrahydrofolate cofactors used in 1-carbon transfer chemistry. In humans, the DHFR enzyme is encoded by the DHFR gene.[1][2] It is found in the q11→q22 region of chromosome 5.[3] Bacterial species possesses distinct DHFR enzymes (based on their pattern of binding diaminoheterocyclic molecules), but mammalian DHFRs are highly similar.[4]
Contents
- 1 Structure
- 2 Function
- 3 Mechanism
- 4 Clinical significance
- 5 Therapeutic applications
- 5.1 Potential anthrax treatment
- 6 As a research tool
- 7 Interactions
- 8 Interactive pathway map
- 9 References
- 10 Further reading
- 11 External links
Structure
A central eight-stranded beta-pleated sheet makes up the main feature of the polypeptide backbone folding of DHFR.[5] Seven of these strands are parallel and the eighth runs antiparallel. Four alpha helices connect successive beta strands.[6] Residues 9 – 24 are termed “Met20” or “loop 1” and, along with other loops, are part of the major subdomain that surround the active site.[7] The active site is situated in the N-terminal half of the sequence, which includes a conserved Pro-Trp dipeptide; the tryptophan has been shown to be involved in the binding of substrate by the enzyme.[8]
|
Function
Dihydrofolate reductase converts dihydrofolate into tetrahydrofolate, a methyl group shuttle required for the de novo synthesis of purines, thymidylic acid, and certain amino acids. While the functional dihydrofolate reductase gene has been mapped to chromosome 5, multiple intronless processed pseudogenes or dihydrofolate reductase-like genes have been identified on separate chromosomes.[9]
|
Found in all organisms, DHFR has a critical role in regulating the amount of tetrahydrofolate in the cell. Tetrahydrofolate and its derivatives are essential for purine and thymidylate synthesis, which are important for cell proliferation and cell growth.[10] DHFR plays a central role in the synthesis of nucleic acid precursors, and it has been shown that mutant cells that completely lack DHFR require glycine, an amino acid, and thymidine to grow.[11] DHFR has also been demonstrated as an enzyme involved in the salvage of tetrahydrobiopterin from dihydrobiopterin [12]
Mechanism
The reduction of dihydrofolate to tetrahydrofolate.
DHFR catalyzes the transfer of a hydride from NADPH to dihydrofolate with an accompanying protonation to produce tetrahydrofolate.[10] In the end, dihydrofolate is reduced to tetrahydrofolate and NADPH is oxidized to NADP+. The high flexibility of Met20 and other loops near the active site play a role in promoting the release of the product, tetrahydrofolate. In particular the Met20 loop helps stabilize the nicotinamide ring of the NADPH to promote the transfer of the hydride from NADPH to dihydrofolate.[7]
Clinical significance
Dihydrofolate reductase deficiency has been linked to megaloblastic anemia.[9] Treatment is with reduced forms of folic acid. Because tetrahydrofolate, the product of this reaction, is the active form of folate in humans, inhibition of DHFR can cause functional folate deficiency. DHFR is an attractive pharmaceutical target for inhibition due to its pivotal role in DNA precursor synthesis. Trimethoprim, an antibiotic, inhibits bacterial DHFR while methotrexate, a chemotherapy agent, inhibits mammalian DHFR. However, resistance has developed against some drugs, as a result of mutational changes in DHFR itself.[13]
Therapeutic applications
Main article: Dihydrofolate reductase inhibitor
Since folate is needed by rapidly dividing cells to make thymine, this effect may be used to therapeutic advantage.
DHFR can be targeted in the treatment of cancer. DHFR is responsible for the levels of tetrahydrofolate in a cell, and the inhibition of DHFR can limit the growth and proliferation of cells that are characteristic of cancer. Methotrexate, a competitive inhibitor of DHFR, is one such anticancer drug that inhibits DHFR.[14] Other drugs include trimethoprim and pyrimethamine. These three are widely used as antitumor and antimicrobial agents.[15] Whether or not these are potent anticancer agents is unclear.
Trimethoprim has shown to have activity against a variety of Gram-positive bacterial pathogens.[16] However, resistance to trimethoprim and other drugs aimed at DHFR can arise due to a variety of mechanisms, limiting the success of their therapeutical uses.[17][18][19] Resistance can arise from DHFR gene amplification, mutations in DHFR, decrease in the uptake of the drugs, among others. Regardless, trimethoprim and sulfamethoxazole in combination has been used as an antibacterial agent for decades.[16]
Folic acid is necessary for growth,[20] and the pathway of the metabolism of folic acid is a target in developing treatments for cancer. DHFR is one such target. A regimen of fluorouracil, doxorubicin, and methotrexate was shown to prolong survival in patients with advanced gastric cancer.[21] Further studies into inhibitors of DHFR can lead to more ways to treat cancer.
Bacteria also need DHFR to grow and multiply and hence inhibitors selective for bacterial DHFR have found application as antibacterial agents.[16]
Classes of small-molecules employed as inhibitors of dihydrofolate reductase include diaminoquinazoline & diaminopyrroloquinazoline,[22] diaminopyrimidine, diaminopteridine and diaminotriazines.[23]
Potential anthrax treatment
Structural alignment of dihydrofolate reductase from Bacillus anthracis (BaDHFR), Staphylococcus aureus (SaDHFR), Escherichia coli (EcDHFR), and Streptococcus pneumoniae (SpDHFR).
Dihydrofolate reductase from Bacillus anthracis (BaDHFR) a validated drug target in the treatment of the infectious disease, anthrax. BaDHFR is less sensitive to trimethoprim analogs than is dihydrofolate reductase from other species such as Escherichia coli, Staphylococcus aureus, and Streptococcus pneumoniae. A structural alignment of dihydrofolate reductase from all four species shows that only BaDHFR has the combination phenylalanine and tyrosine in positions 96 and 102, respectively.
BaDHFR's resistance to trimethoprim analogs is due to these two residues (F96 and Y102), which also confer improved kinetics and catalytic efficiency.[24] Current research uses active site mutants in BaDHFR to guide lead optimization for new antifolate inhibitors.[24]
As a research tool
DHFR has been used as a tool to detect protein-protein interactions in a protein-fragment complementation assay (PCA).
Interactions
Dihydrofolate reductase has been shown to interact with GroEL[25] and Mdm2.[26]
Interactive pathway map
Click on genes, proteins and metabolites below to link to respective articles. [§ 1]
[[File:
|{{{bSize}}}px|alt=Fluorouracil (5-FU) Activity edit]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
File:FluoropyrimidineActivity_WP1601.png
Fluorouracil (5-FU) Activity edit- ^ The interactive pathway map can be edited at WikiPathways: "FluoropyrimidineActivity_WP1601".
References
- ^ Chen MJ, Shimada T, Moulton AD, Harrison M, Nienhuis AW (December 1982). "Intronless human dihydrofolate reductase genes are derived from processed RNA molecules". Proc. Natl. Acad. Sci. U.S.A. 79 (23): 7435–9. doi:10.1073/pnas.79.23.7435. PMC 347354. PMID 6961421.
- ^ Chen MJ, Shimada T, Moulton AD, Cline A, Humphries RK, Maizel J, Nienhuis AW (March 1984). "The functional human dihydrofolate reductase gene". J. Biol. Chem. 259 (6): 3933–43. PMID 6323448.
- ^ Funanage VL, Myoda TT, Moses PA, Cowell HR (October 1984). "Assignment of the human dihydrofolate reductase gene to the q11----q22 region of chromosome 5". Mol. Cell. Biol. 4 (10): 2010–6. PMC 369017. PMID 6504041.
- ^ Smith SL, Patrick P, Stone D, Phillips AW, Burchall JJ (November 1979). "Porcine liver dihydrofolate reductase. Purification, properties, and amino acid sequence". J. Biol. Chem. 254 (22): 11475–84. PMID 500653.
- ^ Matthews DA, Alden RA, Bolin JT, Freer ST, Hamlin R, Xuong N, Kraut J, Poe M, Williams M, Hoogsteen K (July 1977). "Dihydrofolate reductase: x-ray structure of the binary complex with methotrexate". Science 197 (4302): 452–5. doi:10.1126/science.17920. PMID 17920.
- ^ Filman DJ, Bolin JT, Matthews DA, Kraut J (November 1982). "Crystal structures of Escherichia coli and Lactobacillus casei dihydrofolate reductase refined at 1.7 A resolution. II. Environment of bound NADPH and implications for catalysis". J. Biol. Chem. 257 (22): 13663–72. PMID 6815179.
- ^ a b Osborne MJ, Schnell J, Benkovic SJ, Dyson HJ, Wright PE (August 2001). "Backbone dynamics in dihydrofolate reductase complexes: role of loop flexibility in the catalytic mechanism". Biochemistry 40 (33): 9846–59. doi:10.1021/bi010621k. PMID 11502178.
- ^ Bolin JT, Filman DJ, Matthews DA, Hamlin RC, Kraut J (November 1982). "Crystal structures of Escherichia coli and Lactobacillus casei dihydrofolate reductase refined at 1.7 A resolution. I. General features and binding of methotrexate". J. Biol. Chem. 257 (22): 13650–62. PMID 6815178.
- ^ a b "Entrez Gene: DHFR dihydrofolate reductase".
- ^ a b Schnell JR, Dyson HJ, Wright PE (2004). "Structure, dynamics, and catalytic function of dihydrofolate reductase". Annu Rev Biophys Biomol Struct 33 (1): 119–40. doi:10.1146/annurev.biophys.33.110502.133613. PMID 15139807.
- ^ Urlaub G, Chasin LA (July 1980). "Isolation of Chinese hamster cell mutants deficient in dihydrofolate reductase activity". Proc. Natl. Acad. Sci. U.S.A. 77 (7): 4216–20. doi:10.1073/pnas.77.7.4216. PMC 349802. PMID 6933469.
- ^ Crabtree MJ, Tatham AL, Hale AB, Alp NJ, Channon KM (2009). "Critical role for tetrahydrobiopterin recycling by dihydrofolate reductase in regulation of endothelial nitric-oxide synthase coupling: relative importance of the de novo biopterin synthesis versus salvage pathways". J. Biol. Chem. 284 (41): 28128–36. doi:10.1074/jbc.M109.041483. PMC 2788863. PMID 19666465.
- ^ Cowman AF, Lew AM (November 1989). "Antifolate drug selection results in duplication and rearrangement of chromosome 7 in Plasmodium chabaudi". Mol. Cell. Biol. 9 (11): 5182–8. PMC 363670. PMID 2601715.
- ^ Li R, Sirawaraporn R, Chitnumsub P, Sirawaraporn W, Wooden J, Athappilly F, Turley S, Hol WG (January 2000). "Three-dimensional structure of M. tuberculosis dihydrofolate reductase reveals opportunities for the design of novel tuberculosis drugs". J. Mol. Biol. 295 (2): 307–23. doi:10.1006/jmbi.1999.3328. PMID 10623528.
- ^ Benkovic SJ, Fierke CA, Naylor AM (March 1988). "Insights into enzyme function from studies on mutants of dihydrofolate reductase". Science 239 (4844): 1105–10. doi:10.1126/science.3125607. PMID 3125607.
- ^ a b c Hawser S, Lociuro S, Islam K (March 2006). "Dihydrofolate reductase inhibitors as antibacterial agents". Biochem. Pharmacol. 71 (7): 941–8. doi:10.1016/j.bcp.2005.10.052. PMID 16359642.
- ^ Narayana N, Matthews DA, Howell EE, Nguyen-huu X (November 1995). "A plasmid-encoded dihydrofolate reductase from trimethoprim-resistant bacteria has a novel D2-symmetric active site". Nat. Struct. Biol. 2 (11): 1018–25. doi:10.1038/nsb1195-1018. PMID 7583655.
- ^ Huennekens FM (June 1996). "In search of dihydrofolate reductase". Protein Sci. 5 (6): 1201–8. doi:10.1002/pro.5560050626. PMC 2143423. PMID 8762155.
- ^ Banerjee D, Mayer-Kuckuk P, Capiaux G, Budak-Alpdogan T, Gorlick R, Bertino JR (July 2002). "Novel aspects of resistance to drugs targeted to dihydrofolate reductase and thymidylate synthase". Biochim. Biophys. Acta 1587 (2-3): 164–73. doi:10.1016/S0925-4439(02)00079-0. PMID 12084458.
- ^ Bailey SW, Ayling JE (2009). "The extremely slow and variable activity of dihydrofolate reductase in human liver and its implications for high folic acid intake". Proc. Natl. Acad. Sci. U.S.A. 106 (36): 15424–9. doi:10.1073/pnas.0902072106. PMC 2730961. PMID 19706381.
- ^ Murad AM, Santiago FF, Petroianu A, Rocha PR, Rodrigues MA, Rausch M (July 1993). "Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer". Cancer 72 (1): 37–41. doi:10.1002/1097-0142(19930701)72:1<37::AID-CNCR2820720109>3.0.CO;2-P. PMID 8508427.
- ^ Srinivasan B and Skolnick J (2015). "Insights into the slow-onset tight-binding inhibition of Escherichia coli dihydrofolate reductase: detailed mechanistic characterization of pyrrolo [3,2-f] quinazoline-1,3-diamine and its derivatives as novel tight-binding inhibitors.". FEBS J 282 (10): 1922–1938. doi:10.1111/febs.13244. PMID 25703118.
- ^ Srinivasan B, Tonddast-Navaei S and Skolnick J (2015). "Ligand binding studies, preliminary structure-activity relationship and detailed mechanistic characterization of 1-phenyl-6,6-dimethyl-1,3,5-triazine-2,4-diamine derivatives as inhibitors of Escherichia coli dihydrofolate reductase.". Eur J Med Chem. 103: 600–614. doi:10.1016/j.ejmech.2015.08.021. PMID 26414808.
- ^ a b Beierlein JM, Karri NG, Anderson AC (October 2010). "Targeted mutations of Bacillus anthracis dihydrofolate reductase condense complex structure−activity relationships". J. Med. Chem. 53 (20): 7327–36. doi:10.1021/jm100727t. PMC 3618964. PMID 20882962.
- ^ Mayhew M, da Silva AC, Martin J, Erdjument-Bromage H, Tempst P, Hartl FU (February 1996). "Protein folding in the central cavity of the GroEL-GroES chaperonin complex". Nature 379 (6564): 420–6. doi:10.1038/379420a0. PMID 8559246.
- ^ Maguire M, Nield PC, Devling T, Jenkins RE, Park BK, Polański R, Vlatković N, Boyd MT (May 2008). "MDM2 regulates dihydrofolate reductase activity through monoubiquitination". Cancer Res. 68 (9): 3232–42. doi:10.1158/0008-5472.CAN-07-5271. PMC 3536468. PMID 18451149.
Further reading
- Joska TM, Anderson AC (October 2006). "Structure-activity relationships of Bacillus cereus and Bacillus anthracis dihydrofolate reductase: toward the identification of new potent drug leads". Antimicrob. Agents Chemother. 50 (10): 3435–43. doi:10.1128/AAC.00386-06. PMC 1610094. PMID 17005826.
- Chan DC, Fu H, Forsch RA, Queener SF, Rosowsky A (June 2005). "Design, synthesis, and antifolate activity of new analogues of piritrexim and other diaminopyrimidine dihydrofolate reductase inhibitors with omega-carboxyalkoxy or omega-carboxy-1-alkynyl substitution in the side chain". J. Med. Chem. 48 (13): 4420–31. doi:10.1021/jm0581718. PMID 15974594.
- Banerjee D, Mayer-Kuckuk P, Capiaux G, Budak-Alpdogan T, Gorlick R, Bertino JR (2002). "Novel aspects of resistance to drugs targeted to dihydrofolate reductase and thymidylate synthase". Biochim. Biophys. Acta 1587 (2-3): 164–73. doi:10.1016/S0925-4439(02)00079-0. PMID 12084458.
- Stockman BJ, Nirmala NR, Wagner G, Delcamp TJ, DeYarman MT, Freisheim JH (1992). "Sequence-specific 1H and 15N resonance assignments for human dihydrofolate reductase in solution". Biochemistry 31 (1): 218–29. doi:10.1021/bi00116a031. PMID 1731871.
- Beltzer JP, Spiess M (1991). "In vitro binding of the asialoglycoprotein receptor to the beta adaptin of plasma membrane coated vesicles". EMBO J. 10 (12): 3735–42. PMC 453108. PMID 1935897.
- Davies JF, Delcamp TJ, Prendergast NJ, Ashford VA, Freisheim JH, Kraut J (1990). "Crystal structures of recombinant human dihydrofolate reductase complexed with folate and 5-deazafolate". Biochemistry 29 (40): 9467–79. doi:10.1021/bi00492a021. PMID 2248959.
- Will CL, Dolnick BJ (1989). "5-Fluorouracil inhibits dihydrofolate reductase precursor mRNA processing and/or nuclear mRNA stability in methotrexate-resistant KB cells". J. Biol. Chem. 264 (35): 21413–21. PMID 2592384.
- Masters JN, Attardi G (1985). "Discrete human dihydrofolate reductase gene transcripts present in polysomal RNA map with their 5' ends several hundred nucleotides upstream of the main mRNA start site". Mol. Cell. Biol. 5 (3): 493–500. PMC 366741. PMID 2859520.
- Miszta H, Dabrowski Z, Lanotte M (1988). "In vitro patterns of enzymic tetrahydrofolate dehydrogenase (EC 1.5.1.3) expression in bone marrow stromal cells". Leukemia 2 (11): 754–9. PMID 3185016.
- Oefner C, D'Arcy A, Winkler FK (1988). "Crystal structure of human dihydrofolate reductase complexed with folate". Eur. J. Biochem. 174 (2): 377–85. doi:10.1111/j.1432-1033.1988.tb14108.x. PMID 3383852.
- Yang JK, Masters JN, Attardi G (1984). "Human dihydrofolate reductase gene organization. Extensive conservation of the G + C-rich 5' non-coding sequence and strong intron size divergence from homologous mammalian genes". J. Mol. Biol. 176 (2): 169–87. doi:10.1016/0022-2836(84)90419-4. PMID 6235374.
- Masters JN, Yang JK, Cellini A, Attardi G (1983). "A human dihydrofolate reductase pseudogene and its relationship to the multiple forms of specific messenger RNA". J. Mol. Biol. 167 (1): 23–36. doi:10.1016/S0022-2836(83)80032-1. PMID 6306253.
- Chen MJ, Shimada T, Moulton AD, Cline A, Humphries RK, Maizel J, Nienhuis AW (1984). "The functional human dihydrofolate reductase gene". J. Biol. Chem. 259 (6): 3933–43. PMID 6323448.
- Funanage VL, Myoda TT, Moses PA, Cowell HR (1984). "Assignment of the human dihydrofolate reductase gene to the q11----q22 region of chromosome 5". Mol. Cell. Biol. 4 (10): 2010–6. PMC 369017. PMID 6504041.
- Masters JN, Attardi G (1983). "The nucleotide sequence of the cDNA coding for the human dihydrofolic acid reductase". Gene 21 (1-2): 59–63. doi:10.1016/0378-1119(83)90147-6. PMID 6687716.
- Morandi C, Masters JN, Mottes M, Attardi G (1982). "Multiple forms of human dihydrofolate reductase messenger RNA. Cloning and expression in Escherichia coli of their DNA coding sequence". J. Mol. Biol. 156 (3): 583–607. doi:10.1016/0022-2836(82)90268-6. PMID 6750132.
- Bonifaci N, Sitia R, Rubartelli A (1995). "Nuclear translocation of an exogenous fusion protein containing HIV Tat requires unfolding". AIDS 9 (9): 995–1000. doi:10.1097/00002030-199509000-00003. PMID 8527095.
- Mayhew M, da Silva AC, Martin J, Erdjument-Bromage H, Tempst P, Hartl FU (1996). "Protein folding in the central cavity of the GroEL-GroES chaperonin complex". Nature 379 (6564): 420–6. doi:10.1038/379420a0. PMID 8559246.
- Gross M, Robinson CV, Mayhew M, Hartl FU, Radford SE (1996). "Significant hydrogen exchange protection in GroEL-bound DHFR is maintained during iterative rounds of substrate cycling". Protein Sci. 5 (12): 2506–13. doi:10.1002/pro.5560051213. PMC 2143321. PMID 8976559.
- Schleiff E, Shore GC, Goping IS (1997). "Human mitochondrial import receptor, Tom20p. Use of glutathione to reveal specific interactions between Tom20-glutathione S-transferase and mitochondrial precursor proteins". FEBS Lett. 404 (2-3): 314–8. doi:10.1016/S0014-5793(97)00145-2. PMID 9119086.
- Cody V, Galitsky N, Luft JR, Pangborn W, Rosowsky A, Blakley RL (1997). "Comparison of two independent crystal structures of human dihydrofolate reductase ternary complexes reduced with nicotinamide adenine dinucleotide phosphate and the very tight-binding inhibitor PT523". Biochemistry 36 (45): 13897–903. doi:10.1021/bi971711l. PMID 9374868.
- Vanguri VK, Wang S, Godyna S, Ranganathan S, Liau G (2000). "Thrombospondin-1 binds to polyhistidine with high affinity and specificity". Biochem. J. 347 (Pt 2): 469–73. doi:10.1042/0264-6021:3470469. PMC 1220979. PMID 10749676.
External links
- 1988 Nobel lecture in Medicine
- Proteopedia: Dihydrofolate reductase
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
This article incorporates text from the public domain Pfam and InterPro IPR001796
This article incorporates text from the public domain Pfam and InterPro IPR009159
UpToDate Contents
全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.
- 1. 高用量メトトレキサートの治療使用および毒性 therapeutic use and toxicity of high dose methotrexate
- 2. 移植片対宿主病の予防および治療に使用される免疫抑制剤の概要 overview of immunosuppressive agents used for prevention and treatment of graft versus host disease
- 3. クローン病における免疫調節療法 immunomodulator therapy in crohn disease
- 4. 抗マラリア剤：概要 antimalarial drugs an overview
- 5. 低用量メトトレキサートの主な副作用 major side effects of low dose methotrexate
English Journal
- Regulation of the cancer cell membrane lipid composition by NaCHOleate: Effects on cell signaling and therapeutical relevance in glioma.
- Lladó V1, López DJ1, Ibarguren M1, Alonso M1, Soriano JB2, Escribá PV1, Busquets X3.
- Biochimica et biophysica acta.Biochim Biophys Acta.2014 Jun;1838(6):1619-1627. doi: 10.1016/j.bbamem.2014.01.027. Epub 2014 Feb 10.
- This review summarizes the cellular bases of the effects of NaCHOleate (2-hydroxyoleic acid; 2OHOA; Minerval) against glioma and other types of tumors. NaCHOleate, activates sphingomyelin synthase (SGMS) increasing the levels of cell membrane sphingomyelin (SM) and diacylglycerol (DAG) together with
- PMID 24525074
- Competition between Plasmodium falciparum strains in clinical infections during in vitro culture adaptation.
- Chen K1, Sun L1, Lin Y2, Fan Q3, Zhao Z3, Hao M1, Feng G4, Wu Y5, Cui L6, Yang Z7.
- Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases.Infect Genet Evol.2014 Jun;24:105-10. doi: 10.1016/j.meegid.2014.03.012. Epub 2014 Mar 22.
- We evaluated the dynamics of parasite populations during in vitro culture adaptation in 15 mixed Plasmodium falciparum infections, which were collected from a hypoendemic area near the China-Myanmar border. Allele types at the msp1 block 2 in the initial clinical samples and during subsequent cultur
- PMID 24667050
- Substantial increase in mutations in the genes pfdhfr and pfdhps puts sulphadoxine-pyrimethamine-based intermittent preventive treatment for malaria at risk in Burkina Faso.
- Geiger C1, Compaore G, Coulibaly B, Sie A, Dittmer M, Sanchez C, Lanzer M, Jänisch T.
- Tropical medicine & international health : TM & IH.Trop Med Int Health.2014 Jun;19(6):690-697. doi: 10.1111/tmi.12305. Epub 2014 Mar 27.
- OBJECTIVE: Sulphadoxine-pyrimethamine (SP) is widely used as intermittent preventive treatment (IPT) for malaria in pregnant women in Sub-Saharan Africa. There are reports of wide-spread SP resistance in countries where SP had once been used as a first-line treatment. It is unclear whether the devel
- PMID 24674355
Japanese Journal
- A-to-I RNA editing up-regulates human dihydrofolate reductase in breast cancer
- Nakano Masataka,Fukami Tatsuki,Gotoh Saki,Nakajima Miki
- Journal of Biological Chemistry 292(12), 4873-4884, 2017-03-24
- … Dihydrofolate reductase (DHFR) plays a key role in folate metabolism and is a target molecule of methotrexate. … An increase in the cellular expression level of DHFR is one of the mechanisms of tumor resistance to methotrexate. … The present study investigated the possibility that adenosine-to-inosine RNA editing, which causes nucleotide conversion by adenosine deaminase acting on RNA (ADAR) enzymes, might modulate DHFR expression. …
- NAID 120006306229
- 高圧力下における深海生物由来ジヒドロ葉酸還元酵素DHFR構造動態の計算科学研究
- 米澤 康滋
- 近畿大学先端技術総合研究所紀要 = Memoirs of Institute of Advanced Technology, Kinki University (20), 9-18, 2015-03
- … 本研究では, 深海生物Moritella profunda のDHFR を, Escherichia coli のDHFR と比較することでその構造及び機能動態・構造揺らぎ, 及びその圧力依存性を様々な手法で解析した. … その結果, 深海生物由来DHFR の構造揺らぎは高圧力下でも機能を失わないような独自な構造動態を示す進化を遂げていることを示唆する結果を得た. …
- NAID 120005736504
- Gene-Nutrient Interaction between Folate and Dihydrofolate Reductase in Risk for Adenomatous Polyp Occurrence: A Preliminary Report
- CHOI Jeong-hwa,YATES Zoe,MARTIN Charlotte [他],BOYD Lyndell,NG Xiaowei,SKINNER Virginia,WAI Ron,VEYSEY Martin,LUCOCK Mark
- Ｊｏｕｒｎａｌ ｏｆ Ｎｕｔｒｉｔｉｏｎａｌ Ｓｃｉｅｎｃｅ ａｎｄ Ｖｉｔａｍｉｎｏｌｏｇｙ 61(6), 455-459, 2015
- … Dihydrofolate reductase (DHFR) is critical in the metabolism of synthetic folic acid (pteroylmonoglutamatamic, PteGlu) to tetrahydrofolate following absorption. … Therefore, the 19bp deletion variant of DHFR may lead to the alteration of folate-related colorectal disease susceptibility. … This study examined the association between PteGlu and 19bp del-DHFR, and adenomatous polyp (AP) occurrence, an antecedent of colorectal cancer. …
- NAID 130005125482
Related Pictures
★リンクテーブル★
| リンク元 | 「ジヒドロ葉酸還元酵素」「dihydrofolate reductase」 |
| 関連記事 | 「DHF」「DH」 |
「ジヒドロ葉酸還元酵素」
- 英
- dihydrofolate reductase DHFR
- 同
- ジヒドロ葉酸レダクターゼ、テトラヒドロ葉酸脱水素酵素 tetrahydrofolate dehydrogenase
- 関
- 葉酸、ジヒドロ葉酸。抗葉酸薬
「dihydrofolate reductase」
- 同
- DHFR
- 同
- DHFR
- 同
- DHFR
- 同
- DHFR
「DHF」
- 同
- dihydrofolate, ジヒドロ葉酸